ArticleBlood neoplasia2026

CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study.

Shivani Handa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.